Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

EB-101

Cell therapy · Gene replacement · developed by Abeona Therapeutics

Phase 3 Most advanced trial
ABEO Developer
2 Registered trials

What is EB-101?

EB-101 is an autologous cell therapy consisting of patient-derived keratinocytes transduced with a recombinant retrovirus carrying a full-length COL7A1 expression cassette to restore type VII collagen production. It is being studied in recessive dystrophic epidermolysis bullosa (RDEB).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
pz-cel
Drug type
Cell therapy
Mechanism
Gene replacement
Therapy area
Dermatology
Developer
Abeona Therapeutics, Inc (ABEO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05725018 Phase 3 Epidermolysis Bullosa Active not recruiting ABEO
NCT04227106 Phase 3 Epidermolysis Bullosa Completed ABEO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

RDEBEpidermolysis BullosaRecessive Dystrophic Epidermolysis Bullosa

More from Abeona Therapeutics

ABO-101 N/A LZRSE-Col7A1 Phase 1/2 MSI-78 Phase 3 Pz-cel Phase 4 rAAV9.CMV.hNAGLU Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ABEO page.

Follow ABEO, the company behind EB-101

See ABEO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABEO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.